article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

It is too early to say because we have not seen the whole package of measures yet. THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2004. One of the key priorities of the EU’s strategy is to encourage innovation to solve unmet medical needs. THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2006.

article thumbnail

FDA Issues Two Guidance Documents on Food Allergen Labeling Requirements

The FDA Law Blog

All packaged foods served or sold on transportation carriers (e.g., 1, 2023; The applicability of food allergen labeling requirements to specific products (e.g., labeling of major food allergens in bulk foods, dietary supplements, protein-free ingredients, and foods produced through genetic engineering); and.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Care … Amazon’s Revolutionary Move into Healthcare

Fuld

In just three years, Amazon has put together a package of leading-edge services that have the potential to revolutionize the US healthcare market. Five months later in June, it announced the $753 million acquisition of PillPack and its move into the drug supply chain with mail order pouch packaging services. .

article thumbnail

Five potential EU regulatory changes impacting the life sciences industry in 2023

European Pharmaceutical Review

Launch of the EU pharmaceutical package The European Commission plans to commence initiatives relating to the European Pharmaceutical Strategy (strategy) with the publication of the revised EU pharmaceutical package scheduled during the first quarter of 2023.

Packaging 117
article thumbnail

Why Are FDA Inspections So Ineffective and Disappointing?

The People's Pharmacy

“The FDA said Global Pharma failed to use adequate, tamper-evident packaging and distributed the drugs without proper preservatives.” What is extraordinary about this scandal is that the FDA inspected one of the Ranbaxy facilities in 2004. This was around the time the whistleblower was discovering serious problems.

FDA 72
article thumbnail

Hashimoto’s and Graves’ Remission after Helicobacter Pylori Eradication

The Thyroid Pharmacist

Source: Bertalot et al, 2004). Source: Bertalot et al, 2004). MegaGuard and PyloGuard provide doses on the package. Reduction in TPO antibodies ranged from 50 to 99 percent, while reduction of TG antibodies ranged from 31 to 95 percent over the course of 17 to 22 months. (23). The five patients with Hashimoto’s and untreated H.

article thumbnail

Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure

PharmaShots

R&D Expenditure: $7.19B Founded Year: 2004 Total Employees: ~91,573,440 Headquarters: Paris, France Market Cap: $143.9B In Nov 2021, GSK entered into a license agreement with Arrowhead to develop and commercialize Arrowhead’s RNAi therapy, ARO-HSD. R&D Expenditure: $14.6B